Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Tscan Therapeutics Inc (TCRX)

58 + Investors. Track Smart Money conviction in TCRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
→ 0
Streak
1Q —
Buyers last Q
59%

Smart Money Signals — TCRX

Based on 58 hedge funds · latest filing: 2026 Q2 · updated quarterly

➡️

No change last quarter

last 6Q
The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.
🔻

Below peak — only 63% of 3.0Y high

63% of all-time peak
Only 58 funds hold TCRX today versus a peak of 92 funds at 2025 Q1 — just 63% of the maximum. Low institutional ownership can mean the stock is out of favor, but it also means there's a large pool of potential buyers if sentiment turns.
📉

Outflows — 27% fewer funds vs a year ago

fund count last 6Q
21 fewer hedge funds hold TCRX compared to a year ago (-27% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟡

Slight buying edge — 59% buying

29 buying20 selling
Last quarter: 29 funds bought or added vs 20 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~8 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 6 → 9 → 11 → 8. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

55% of holders stayed for 2+ years

■ 55% conviction (2yr+) ■ 26% medium ■ 19% new
32 out of 58 hedge funds have held TCRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
➡️

Steady discovery — ~8 new funds/quarter

20 → 6 → 9 → 11 → 8 new funds/Q
New funds entering each quarter: 6 → 9 → 11 → 8. Consistent flow of new institutional buyers without clear acceleration or slowdown.
🏛️

Veteran-anchored — 59% veterans vs 22% newcomers

■ 59% veterans ■ 19% 1-2yr ■ 22% new
Entry-cohort mix of 58 holders: 34 (59%) are 2+ year veterans, 11 entered 1–2 years ago, and 13 (22%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 21% AUM from major funds

21% from top-100 AUM funds
20 of 58 holders rank in the top 100 by AUM, accounting for 21% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
1.6
out of 10
Low Exit Risk
Exit risk score 1.6/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — TCRX

In 2026 Q2, 29 hedge funds were net buyers of TCRX (8 opened a new position, 21 added to an existing one), while 20 reduced or exited (12 trimmed, 8 sold completely) — a 59% buyer ratio, indicating a slight buying edge. 21% of total institutional value in TCRX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: flat (entries and exits balanced). Total institutional holders: 58.

Hedge Fund Ownership: TCRX

How many hedge funds hold TCRX — quarterly history vs. share price
Quarterly hedge fund ownership of TCRX vs. share price

Market Analysis: TCRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: TCRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Tscan Therapeutics Inc (TCRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much TCRX has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 54d ago
TCRX
-20.4%
XLV
+10.1%

TCRX outperformed XLV by -30.5% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 9d ago
TCRX
+0.1%
XLV
+4.3%

Since the filing became public, TCRX outperformed XLV by -4.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 0 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
0.6
/ 10
conviction
Hedge Fund Positioning: TCRX
58 + Investors

Track Smart Money conviction in TCRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 58 58 -
13F Shares 36M 33M 8.56%
Total Value $33M $33M 2.09%
New Positions 8 11 -3
Increased Positions 21 15 +6
Closed Positions 8 11 -3
Reduced Positions 12 18 -6
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: TCRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

58 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TCRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 TCRX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 DC Funds, LP 49.27% 630,000 $617K
2 Lynx1 Capital Management LP 1.55% 8,019,148 $7.9M
3 Kalehua Capital Management LLC 0.32% 454,876 $446K
4 Verdad Advisers, LP 0.22% 232,759 $228K
5 Deer Management Co. LLC 0.15% 1,245,504 $1.2M
6 Bvf Inc/Il 0.14% 5,564,290 $5.5M
7 Baker BROS. Advisors LP 0.01% 2,784,792 $2.7M
8 DC Investments Management, LLC 0.01% 35,563 $35K
9 Boothbay Fund Management, LLC 0.01% 772,241 $757K
10 R Squared Ltd 0.01% 18,360 $18K
11 Jacobs Levy Equity Management, Inc 0.00% 1,049,806 $1.0M
12 Aries Wealth Management 0.00% 10,000 $10K
13 XTX Topco Ltd 0.00% 149,467 $146K
14 Renaissance Technologies LLC 0.00% 1,326,799 $1.3M
15 Landscape Capital Management, L.L.C. 0.00% 25,864 $25K
16 Letko, Brosseau & Associates Inc 0.00% 95,875 $94K
17 Two Sigma Investments, LP 0.00% 1,949,604 $1.9M
18 Bridgeway Capital Management, LLC 0.00% 76,900 $75K
19 NewEdge Wealth, LLC 0.00% 91,463 $90K
20 Brown Brothers Harriman & Co 0.00% 143,051 $140K
21 Marshall Wace, LLP 0.00% 687,364 $674K
22 Millennium Management LLC 0.00% 1,163,611 $1.1M
23 Hrt Financial LP 0.00% 164,601 $161K
24 D. E. Shaw & Co., Inc. 0.00% 548,402 $537K
25 Kestra Advisory Services, LLC 0.00% 62,525 $61K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Tscan Therapeutics Inc (TCRX)

What does the Smart Money Trend signal show for TCRX?

No change last quarter: The number of hedge funds holding this stock didn't change last quarter. Neither a buying nor selling signal on its own — watch the next quarter for direction.

What is the institutional breadth score for TCRX?

Slight buying edge — 59% buying: Last quarter: 29 funds bought or added vs 20 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for TCRX holders?

Strong quality — 21% AUM from major funds: 20 of 58 holders rank in the top 100 by AUM, accounting for 21% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held TCRX?

55% of holders stayed for 2+ years: 32 out of 58 hedge funds have held TCRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Tscan Therapeutics Inc (TCRX) following the 2026 Q2 hedge fund 13F filings?

As of today, TCRX has moved +0.1% since the 2026 Q2 13F filing date (August 14, 2026), compared to +4.3% for the XLV sector ETF — an outperformance of -4.2%. Since the quarter end (June 30, 2026), TCRX has gained -20.4% vs +10.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →